ʻO GC203 kahi lāʻau lapaʻau TIL i hoʻololi ʻia i ka gene vector non-viral i hoʻomohala ʻia me ka hoʻohana ʻana i ka paepae hoʻonui cell DeepTIL® ponoʻī a Juncell Therapeutics a me ka paepae hoʻololi gene NovaGMP®. Hiki iā DeepTIL® ke hoʻoikaika i nā TIL e lawa ka ikaika ʻaʻole pono ka hui pū ʻana o IL-2 ma hope o ka hoʻokomo ʻana, a hiki ke haʻahaʻa ka ikaika o ka mālama mua ʻana. Hoʻololi ʻo NovaGMP® i nā cell T me kahi pono kiʻekiʻe e hoʻohālikelike ʻia me ka vector Lentiviral ma ke ʻano waiwai. Hoʻolālā ʻia ʻo GC203 me ka interleukin-7 i hoʻopaʻa ʻia i ka membrane ponoʻī, hiki ke mālama i ke kumu o nā cell T hoʻomanaʻo, hoʻāla i nā cell pale kūloko a pale i nā mea ʻawaʻawa systemic.
Ua hoʻāʻo nā kānaka noiʻi iā GC203 ma nā poʻe maʻi i ʻike ʻia me ka maʻi ʻaʻai ovarian hou, me ka ʻole o ka hui pū ʻana o ka hoʻokele IL-2 a i ʻole ka lymphodepletion ikaika. ʻO ka pahuhopu o ke aʻo ʻana, ʻo ia ka hoʻoholo ʻana i ka palekana a me ka pono o kēia lāʻau lapaʻau. He 20 mau maʻi i kākau inoa ʻia ma waena o 09/2021 a me 01/2024 i ka hoʻokolohua kikowaena hoʻokahi-kikowaena hāmama, kahi i hiki ke loiloi ʻia he 18 mau maʻi. ʻO nā maʻi loiloi me ka ECOG PS o 1 (55.6%) a i ʻole 2 (44.4%) a loaʻa i ka awelika o 5 mau lāʻau lapaʻau systemic ma mua (pae: 2-11). 9 (50%) mau maʻi i loaʻa i 3 a ʻoi aku paha nā ʻeha tumor. ʻO ka nui o ka lesion target waena he 57 (pae: 13-146) mm.
Ua hōʻike ʻo GC203 i nā hopena hoʻohiki i nā poʻe maʻi me ka maʻi ʻaʻai ovarian e hoʻi hou ana a i ʻole metastatic. Ua hoʻomaikaʻi nui ʻia ke ʻano palekana i hoʻohālikelike ʻia me nā lāʻau lapaʻau TIL maʻamau, mahalo i ka mālama mua ʻana me ka haʻahaʻa haʻahaʻa a me ka hoʻopau ʻana i ka hui pū ʻana o IL-2. ʻO ka hapa nui o nā hanana ʻino (AE) he papa 1 a i ʻole papa 2 a hiki ke hoʻomaha ʻia a hoʻōla ʻia paha e ka lāʻau lapaʻau hōʻailona. ʻAʻohe hanana papa 5 i hana ʻia. Ma ka lā palena o 01/2024, ʻo ka Objective Response Rate (ORR) i loiloi ʻia e ka mea noiʻi he 33.3% (95% CI: 16.3 - 56.3), me 11.1% Complete Response (CR). ʻO ka Disease Control Rate (DCR) he 83.3% (95% CI, 60.8 - 94.2). A ʻo ka helu Survival Overall (OS) 12 mahina he 68.8% (95% CI: 49.3 - 95.9). ʻAʻole i oʻo ka OS waena e like me ka ʻoki ʻana o ka ʻikepili.
I ka makahiki 2023, ua hoʻokomo ʻia ʻo Ms. H i ka haukapila i ka makahiki 2023 ma muli o ka ʻūhā.a me ka ʻeha o ka pūhakaMa ka hoʻokolokolo ʻana, ua ʻike ʻia ua hoʻonui ʻia nā lymph nodes he nui ma ka retroperitoneum, groin, a me nā wahi ʻē aʻe, e hōʻoia ana i kāna maʻi ʻaʻai ovarian serous kiʻekiʻe. No laila, ua hana ʻia ʻo Ms. H i ka chemotherapy, ke ʻoki kino, ka immunotherapy, a me nā mea ʻē aʻe, akā ʻaʻole kūpono ka hopena, a ua hoʻi hou mai ka puʻupuʻu.
No laila, ua komo ʻo Ms. H i ka hoʻokolohua lapaʻau o ka lāʻau lapaʻau TIL cell GC203, a ma hope o hoʻokahi mahina o ka mālama ʻana me GC203, ua emi ka puʻupuʻu ma 37.3%.
Nā Hopena: Hoʻokomo ʻia ʻana o GC203loaʻa ka palekana i ʻae ʻia a me ka hopena ikaika i nā poʻe maʻi OC e hana hou ana me ka palena o ke koho lapaʻau.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Email：myimmnet@163.com
Nā Kuhikuhi
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Ka manawa hoʻouna: Dec-11-2024